DOJ: A Company Created To File Lawsuits Has Wasted 1,500 Hours Of The Government's Time Legal Newsline Former Contributor Opinions expressed by Forbes Contributors are their own.
May 30, 2018 · It seems Biogen 's stock trades with a discount.The majority of the analysts thinks Biogen is currently underpriced. Currently the company is being followed by 15 analyst. The recommendations for the stock contain no sells, 9 times hold and no buys. The average of the current target prices for the stock equals 349,14 USD. Biogen Inc. surged the most this year as its new therapy for a rare and deadly muscle disease started strong in its first full quarter, bolstering chances the drug will become a blockbuster.
Biogen Inc. surged the most this year as its new therapy for a rare and deadly muscle disease started strong in its first full quarter, bolstering chances the drug will become a blockbuster. Feb 12, 2015 · Biogen to bring its global drug portfolio to India 19 Feb, 2010, 12.14AM IST. US-based Biogen Idec plans to roll out its entire range of medicines in the fast-growing, Rs 40,000-crore Indian retail drug market over the next few years through its wholly-owned Indian arm.
In fact, Biogen admitted that in rare cases, Avonex might have caused severe liver injury, including liver failure. But rather than removing Avonex from the market, Biogen merely changed the drug's label to include a "warning", rather than the previous advisory regarding potential liver damage.Tecfidera (dimethyl fumarate) by Biogen Idec: Drug Safety Communication - Case of Rare Brain Infection PML Reported. Audience: Neurology Issue. FDA is warning that a patient with multiple sclerosis (MS) who was being treated with Tecfidera (dimethyl fumarate) developed a rare and serious brain infection called progressive multifocal leukoencephalopathy (PML), and later died.